SCHEMBL24658573

SCHEMBL24658573

CC(C)C(=O)CCOCCNC(=O)CCN1C(=O)CC(C(C)C)C1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
HSD17B10 Q99714 2/20 0.36
POLB P06746 1/20 0.36
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
CYP2C19 P33261 3/20 0.34
CYP3A4 P08684 2/20 0.34
TSHR P16473 2/20 0.32
ALDH1A1 P00352 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11916135 0.99 SMN1; SMN2 (0.36) SMN1; SMN2HPGDHTTHSD17B10POLB
SCHEMBL24658576 0.94 HPGD (0.42) SMN1; SMN2HPGDHTTHSD17B10POLB
SCHEMBL278806 0.92 SMN1; SMN2 (0.35) SMN1; SMN2HPGDHTTHSD17B10POLB
SCHEMBL26725107 0.90 HDAC3 (0.43) SMN1; SMN2HPGDHTTPOLBHDAC3
SCHEMBL16118175 0.90 SMN1; SMN2 (0.37) SMN1; SMN2HPGDHTTHSD17B10POLB
SCHEMBL22134362 0.89 SMN1; SMN2 (0.37) SMN1; SMN2HPGDHTTHSD17B10POLB
SCHEMBL16118174 0.89 SMN1; SMN2 (0.38) SMN1; SMN2HPGDHTTHSD17B10POLB
SCHEMBL24979407 0.89 HDAC3 (0.38) SMN1; SMN2HPGDHTTHSD17B10POLB
SCHEMBL22134405 0.88 DRD2 (0.37) SMN1; SMN2HPGDHTTHSD17B10POLB
SCHEMBL14750411 0.88 SMN1; SMN2 (0.36) SMN1; SMN2HPGDHTTHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158169-A1 LINKERS FOR IMPROVING THE STABILITY OF BIOCONJUGATES AND THE SELECTIVITY OF PAYLOAD RELEASE AUDAX PRIVATE DEBT LLC, AS AGENT 2023-05-25 US disclosed
WO-2023077129-A1 TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD TAMBO, INC. (US) 2023-05-04 WO disclosed
US-20220409740-A1 pH Responsive Block Copolymers Compositions, Micelles, and Methods of Use ONCONANO MEDICINE, INC. 2022-12-29 US disclosed
WO-2022165335-A1 LINKERS FOR IMPROVING THE STABILITY OF BIOCONJUGATES AND THE SELECTIVITY OF PAYLOAD RELEASE EqIP, LLC (US) 2022-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409740-A1 pH Responsive Block Copolymers Compositions, Micelles, and Methods of Use MCL1, HRAS, TP53 SMN1; SMN2 1043/4885HPGD 1036/4885HTT 4114/4885
US-20230158169-A1 LINKERS FOR IMPROVING THE STABILITY OF BIOCONJUGATES AND THE SELECTIVITY OF PAYLOAD RELEASE CTSA, CTSS, CTSV SMN1; SMN2 763/4885HPGD 4459/4885HTT 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.